News
Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback